COST-EFFECTIVENESS OF CELECOXIB VERSUS IBUPROFEN AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS IN UNITED ARAB EMIRATES AND SAUDI ARABIA BASED ON RESULTS FROM THE PRECISION TRIAL

被引：0
|
作者：
Ahmed, O. H. [1 ]
Chirikov, V [2 ]
Walker, C. [3 ]
Stephens, J. M. [2 ]
Schepman, P. [4 ]
Chambers, R. [5 ]
Bakir, M. [6 ]
Poorman, G. [7 ]
Haider, S. [8 ]
机构：
[1] Mouwsat Hosp Dammam, Dammam, Saudi Arabia
[2] Pharmerit Int, Bethesda, MD USA
[3] Pfizer, Tadworth, England
[4] Pfizer, New York, NY USA
[5] Pfizer Inc, Collegeville, PA USA
[6] Pfizer, Jeddah, Saudi Arabia
[7] Upjohn Pfizer Inc, New York, NY USA
[8] Pfizer Inc, Groton, CT 06340 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG10
引用
收藏
页码：S130 / S130
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Percutaneous Coronary Intervention Versus Bypass Surgery for Patients With Left Main Disease: Results From the EXCEL Trial
    Magnuson, Elizabeth A.
    Chinnakondepalli, Khaja
    Vilain, Katherine
    Serruys, Patrick W.
    Sabik, Joseph F.
    Kappetein, A. Pieter
    Stone, Gregg W.
    Cohen, David J.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (07) : 590 - 604
  • [22] Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial
    Geisler, Benjamin P.
    Jorgensen, Troels H.
    Thyregod, Hans Gustav H.
    Pietzsch, Jan B.
    Sondergaard, Lars
    EUROINTERVENTION, 2019, 15 (11) : E959 - +
  • [23] Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: Results from the ESPRIT trial
    Cohen, DJ
    Cosgrove, RS
    Berezin, RH
    O'Shea, J
    Kitt, MM
    Gilchrist, I
    Mark, DB
    Tcheng, JE
    CIRCULATION, 2001, 104 (17) : 386 - 387
  • [24] The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial
    B. Jönsson
    J. R. Cook
    T. R. Pedersen
    Diabetologia, 1999, 42 : 1293 - 1301
  • [25] The cost-effectiveness of lipid lowering in patients with diabetes:: results from the 4S trial
    Jönsson, B
    Cook, JR
    Pedersen, TR
    DIABETOLOGIA, 1999, 42 (11) : 1293 - 1301
  • [26] REHABILITATION IN RESURFACING HIP ARTHROPLASTY PATIENTS: PRELIMINARY COST-EFFECTIVENESS RESULTS FROM A CLINICAL TRIAL
    Fusco, F.
    Campbell, H.
    Newman, M.
    Barker, K.
    VALUE IN HEALTH, 2014, 17 (07) : A381 - A382
  • [27] Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial
    Hirotaka Watada
    Hiroyuki Sakamaki
    Daisuke Yabe
    Fumiko Yamamoto
    Tatsunori Murata
    Keigo Hanada
    Tetsuaki Hirase
    Tomoo Okamura
    Diabetes Therapy, 2020, 11 : 1721 - 1734
  • [28] THE COST EFFECTIVENESS OF CELECOXIB VERSUS NSAIDS plus PPI IN THE TREATMENT OF OSTEOARTHRITIS IN ALGERIA; AN UPDATE TO THE NICE MODEL USING DATA FROM THE CONDOR TRIAL
    Mould, J. F.
    Meklati, M.
    Khris, M.
    Kherraf, S. A.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [29] Cost and cost-effectiveness of intravenous enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention: Results from the STEEPLE trial
    Zhao, Liping
    Ewen, Edward
    Zhang, Zefeng
    Bowen, James
    Jurkovitz, Claudine
    Leguet, Prisca
    Kolm, Paul
    Weintraub, William S.
    CIRCULATION, 2006, 114 (18) : 827 - 827
  • [30] Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom collaborative ECMO trial
    Petrou, S
    Bischof, M
    Bennett, C
    Elbourne, D
    Field, D
    McNally, H
    PEDIATRICS, 2006, 117 (05) : 1640 - 1649
12345